Physicians can assess the risks of major coronary events in someone with diabetes reasonably well. Among those with diabetes, there are well-established indicators of risk such as weight, fasting levels of blood glucose and family history of the disease. Doctors also can consider more general measures of health such as cholesterol levels, blood pressure and smoking history.
Until recently, researchers thought that genetic analyses could add relatively little to these factors in predicting CAD risk in people with type 2 diabetes. But now, a study led by Harvard Medical School scientists at Joslin Diabetes Center scientists now has shown that adding genetic factors into the mix can help further hone these risk assessments, said Alessandro Doria, HMS
associate professor of medicine and an investigator in Joslin’s Section on Epidemiology and Genetics.
The study leveraged information gathered in recent years about genes implicated in CAD among the general population, noted Doria, the senior author on a paper describing the research published in Diabetes Care. “The effect is not dramatic, but it is much better than what we expected,” he said.
Joslin scientists used a genetic risk score derived from 160 gene locations now associated with CAD in the population at large, said Doria, who is also an associate professor of medicine at HMS and an associate professor of epidemiology at the Harvard T.H. Chan School of Public Health.
The team examined how well this score applied to people in two studies of type 2 diabetes, the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial and the Outcome-Reduction with an Initial Glargine Intervention (ORIGIN) trial. Scores were calculated for 5,360 ACCORD participants and 1,931 ORIGIN participants.
The results showed that the genetic score provides a significant improvement in the ability to correctly predict future major coronary events, Doria said. The advantage of a score based on genetic markers is that it can be used early in life, when clinical predictors of cardiovascular risk, such as increased body weight or increased cholesterol, may not yet appear.
However, the score doesn’t seem to be useful for predicting which treatments, such as intensive control of blood glucose levels, may help guard against major coronary events.
In previous work, Doria and his colleagues had identified two genes that do help predict whether such treatments would be effective against CAD in type 2 diabetes. Continuing to seek out genetic clues, they then found that lower levels of a protein called GLP-1 are associated with people who will benefit most from intensive control of their blood glucose levels.
Drugs that increase production of this protein are widely used to treat diabetes. It may be that people who produce less GLP-1 when they are under intensive glycemic control receive particular benefits against CAD from such drugs, Doria speculated.
His study shows that large clinical trials such as ACCORD and ORIGIN can continue to provide useful data long after their main conclusions have been gathered. “Ten years after its completion, ACCORD continues to generate ideas and findings,” Doria said.
The research also highlights the role of collaboration across expertise and institutions, he emphasized. For instance, leaders of the ORIGIN trial at McMaster University in Hamilton, Ontario, made key contributions to the work.
Lead funding for this work came from the National Institutes of Health, Grant number R01HL132254.
Adapted from a Joslin News Release.
